Exploiting Iron Metabolism as a Therapeutic Vulnerability in Glioblastoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37982809.
- Also identified by DOI 10.1158/1078-0432.CCR-23-3027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this CCR Translations, we discuss pharmacologic ascorbate as a novel therapeutic for glioblastoma (GBM). Aberrant iron metabolism in GBM can be assessed noninvasively by MRI and exploited to potentially improve the efficacy of chemoradiotherapy. We contextualize the study's results and discuss the next steps to further develop this paradigm. See related article by Petronek et al., p. 283.
Medical subject headings
- Glioblastoma
- Antineoplastic Agents
- Brain Neoplasms